Blog

Oncolytic viruses have emerged as a promising class of cancer therapeutics that combine direct tumor destruction with immune system activation. Unlike traditional oncology treatments, these engineered viruses are designed to selectively infect and replicate within…

Alzheimer’s disease (AD) is increasingly understood not only as a clinical syndrome, but as a biological disease process that begins years before memory loss or other cognitive symptoms become apparent. Because amyloid beta (Aβ) deposition, tau pathology,…

In the early stages of drug research, the ability to predict how a human body will process a chemical is essential for preventing failure in late-stage trials. This predictive ability is primarily driven by in vitro ADME testing, a suite of assays designed to evaluate…

Metabolite identification studies play a central role in modern drug development because they help drug developers understand how a compound is transformed within biological systems and whether resulting metabolites may create additional safety, exposure, or…

A PK study is one of the earliest opportunities in preclinical development to understand how a drug behaves within a biological system, including how it is absorbed, distributed, metabolized, and eliminated over time. While PK studies are often viewed as routine…

Whole Slide Images (WSIs), also known as digital or virtual slides, are digitized images generated from traditional glass slides using specialized hardware and software. WSIs have been widely used as an alternative to glass slides across various clinical diagnostic…

Obesity and type 2 diabetes remain major global health burdens, with WHO estimating that roughly 890 million people were living with obesity in 2022 and 2.5 billion adults were overweight. GLP-1 therapies have already changed treatment expectations, but the larger…

In May 2026, US regulators approved vepdegestrant, the first Proteolysis Targeting Chimera (PROTAC) therapy, marking a historic landmark for this drug class. PROTACs offer an exciting and highly promising alternative to traditional small-molecule inhibitors and…

Precision medicine increasingly depends on understanding not just which biomarkers are present in a tissue sample, but how they interact spatially within the disease microenvironment. Conventional pathology methods – including H&E staining, immunohistochemistry…

Antibody-drug conjugates (ADCs) have emerged as one of the fastest-growing drug modalities in oncology, offering both precision and potency. Their unique structures allow them to bind to their targets while carrying and releasing potent toxins in controlled ways,…

The shift toward precision medicine has altered the landscape of drug development, moving the industry toward therapies tailored to specific biological profiles. The success of these programs depends on the ability to identify, validate, and quantify biological…

The implementation of a cohesive biomarker strategy is one of the most critical elements of getting a drug candidate from early discovery through clinical development. A common pitfall, however, is the assumption that the analytical methods used in early research will…